Keith Pratz, MD, is an Associate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, PA. Dr Pratz obtained his medical degree from the Robert Wood Johnson Medical School, Camden, NJ. He then completed his residency in internal medicine at the Mayo Clinic School of Graduate Medical Education, Rochester, MN, followed by his fellowship in medical oncology at the Johns Hopkins Hospital, Baltimore, MD. Dr Pratz then stayed on at Johns Hopkins University to become the Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, where he also is a clinical investigator into novel treatments for acute leukemias.
Speaking on acute leukemia and novel therapeutics
Dr Pratz has been actively involved in many clinical trials investigating novel therapies for the treatment of acute leukemias, namely the Phase III VIALE-A trial of venetoclax and azacytidine for acute myeloid leukemia (AML). Dr Pratz has also been involved in a prospective study for peri-transplant sorafenib for AML patients undergoing allogeneic transplantation.